Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 5,141 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: AIDS (Acquired Immunodeficiency Syndrome) Clear all

Conditions: HIV Infections
Interventions: PENNVAX-G DNA Vaccine, MVA-CMDR Vaccine, Placebo PENNVAX-G Vaccine, Placebo MVA-CMDR Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: HIV-1-infection
Interventions: EBT-101; Biological
Lead sponsor: Excision BioTherapeutics; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: San Francisco, California • St Louis, Missouri • Camden, New Jersey

Conditions: HIV Infections
Interventions: Tenofovir alafenamide/emtricitabine, GSK3640254; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: HIV, Medication Adherence, Substance Dependence
Interventions: Spiritual Self-Schema Therapy; Behavioral
Lead sponsor: Hunter College of City University of New York; Other
Eligibility: 50 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Homosexuality, Male, HIV, Substance-related Disorders, Sexual Dysfunctions, Psychological
Interventions: MyPeeps Manualized Group Intervention, Standard Sexual Health Education; Behavioral
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 16 Years to 20 Years · Male only
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Prevention, Pre-exposure Prophylaxis
Interventions: Individualized Feedback; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Indinavir sulfate, Rifabutin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 8
States / cities: Los Angeles, California • Denver, Colorado • Miami, Florida + 3 more

Conditions: HIV/AIDS
Interventions: Infectiousness Risk Reduction, General Health Improvement; Behavioral
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 100 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cryptococcal Meningitis
Interventions: Amphotericin B, Fluconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 5 more

Conditions: HCV HIV
Interventions: Ledipasvir 90 mg and Sofosbuvir 400 mg; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: HIV Prevention
Interventions: WERK Supportive Contact; Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 290 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV, Medication Adherence
Interventions: SteadyRx; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Candidiasis, Esophageal, HIV Infections
Interventions: Ketoconazole, Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 41
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 35 more

Conditions: HIV Infections, Tuberculosis
Interventions: Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1999
U.S. locations: 75
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 39 more

Conditions: Hiv
Interventions: Service of care; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: HIV
Interventions: 1% vaginally applied tenofovir gel, Tenofovir film- 10mg, Tenofovir Film-40 mg, HEC Placebo Gel, Placebo Vaginal Film; Drug · Other
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections, Lipoatrophy
Interventions: NucleomaxX, NucleomaxX placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 20 more

Conditions: HIV Infections, AIDS
Interventions: stavudine, efavirenz, lamivudine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 19
States / cities: Berkeley, California • Los Angeles, California • West Hollywood, California + 16 more

Conditions: Alcohol Drinking and Chronic Pain Intervention, Control Condition
Interventions: Motivational and Cognitive-Behavioral Management for Alcohol and Pain (MCBMAP), Treatment as Usual; Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: HIV Infection, Hepatitis B
Interventions: Engerix-B 20 mcg, Engerix-B 40 mcg, Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 24 Years
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 1 more

Conditions: HIV Infection
Interventions: Proleukin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 1,695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV/STI Incidence, Communication About Health Information
Interventions: The Gender Inclusive Sexuality Talks Program, GIST Control; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 12 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: AIDS
Interventions: Hyperbaric chamber; Device
Lead sponsor: Designed Altobaric Technology, Incorporated; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: At Risk for HIV
Interventions: PrEP Smart; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART

Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine

Intervention Targeting Substance Using Older Adults With HIV

HIV Prevention Among Vulnerable Male Youth

Stick2PrEP Cisgender Women and Trans Individuals

Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults

Behavioral Intervention to Enhance HIV Test/Treat

Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis

Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia

Project WERK (Wellness Encouragement Respect Kinship)

SteadyRx: Smartphone ART Adherence Intervention for Drug Users

A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

Virological Suppression in HIV Positive Patients Involved in a Novel Standardized Adherence Protocol

A Phase I Trial to Assess the Safety of Tenofovir Gel and Film Formulations: FAME 04

Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy

Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)

Internet-based Video-conferencing to Address Alcohol Use and Pain: a Pilot Trial

Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth

Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)

The Gender Inclusive Sexuality Talks Program

Effect of Repeated Exposures to Compressed Air on Patients With AIDS

PrEP SMART Phase I Trial